The shortage of the medication — called bacillus Calmette-Guerin, or BCG — has been caused by manufacturing problems at plants operated by two different pharmaceutical companies — Merck and Sanofi Pasteur.
The most advanced vaccine for dengue only offers modest protection but could still help millions...
The imminent patent expiration of Sanofi’s Lantus has opened the door for Eli Lilly to increase...
Sanofi and Eli Lilly and Company today announced an agreement to pursue regulatory approval of...
According to a new report published by Transparency Market Research, "Meningococcal Vaccines Market - Global Industry Analysis 2013 - 2019," the market for meningococcal vaccines was valued at USD 1.5 billion in 2012 and is expected to reach a value of USD 3.7 billion in 2019, growing at a CAGR of 14.9% from 2013 to 2019.
A former pharmaceutical executive has been sentenced to 16 months in prison for his role in an insider trading scheme. John Lazorchak was sentenced Tuesday in federal court in Newark, N.J.
Aastrom Biosciences announced that it has entered into a definitive agreement to acquire Sanofi's Cell Therapy and Regenerative Medicine (CTRM) business for a purchase price of $6.5 million.
Two former pharmaceutical and medical technology firm executives have been sentenced for their involvement in an insider trading scheme.
Sanofi said today its earnings soared in the fourth quarter as lower restructuring costs offset a hefty charge related to one of its key multiple sclerosis treatments.
Sanofi said Tuesday that its insulin U300 met its primary goals in a series of clinical trials, but some results were mixed. U300 is intended to be a longer-lasting version of Lantus that can be administered in lower doses. The company plans to file for marketing approval in the U.S. and European Union in the first half of 2014.
A government study offers a new theory on why the whooping cough vaccine doesn't seem to be working as well as expected. The research suggests that while the vaccine may keep people from getting sick, it doesn't prevent them from spreading whooping cough — also known as pertussis — to others.
Sanofi said its net profit slumped by over a fifth in the third quarter as it continued to suffer the effects of overpaying for acquisitions and a painful restructuring. Sanofi SA said its net profit fell 21 percent to 1.21 billion euros ($1.66 billion) in the July to September quarter, from 1.54 billion euros a year earlier.
A new high-dose flu vaccine for seniors works better than the standard shot in that age group, according to a long-awaited study by the vaccine's manufacturer. Experts say regular flu shots tend to be only about 30 to 40 percent effective in people 65 and older, who generally have weaker immune systems.
John Lazorchak, a former director of financial reporting at Summit-based Celgene Corp., and Mark Cupo, who held a similar position at Sanofi-Aventis, a France-based company with U.S. headquarters in Bridgewater, each pleaded guilty in federal court Monday to five counts of securities fraud.
Sanofi US and its consumer health business Chattem, Inc., have re-introduced Rolaids to stores across the United States. The iconic brand returns after a three-year hiatus in the marketplace and follows Chattem's acquisition of Rolaids earlier this year.
The comments by officials of the European Chamber of Commerce in China follow announcements about fines imposed on dairy suppliers over pricing issues and an investigation into possibly bribery by employees of drug manufacturers GlaxoSmithKline and Sanofi.
Pozen has announced that Sanofi will handle U.S. marketing of its experimental cardiovascular drugs PA8140 and PA32540. The French drugmaker will pay Pozen $15 million upfront, and Pozen could get another $20 million in payments based on milestones before approval of the products. The companies...
Four flu vaccine manufacturers have started or will soon start clinical trials on H7N9 vaccines, with four more expected to conduct trials in the late fall or early winter, says Dr. Robin Robinson. The work will cost the U.S. government about $100 million.
Chinese authorities have launched an investigation against French drugmaker Sanofi following a news report that accused the company of bribing hundreds of Chinese doctors in 2007. An unnamed whistleblower told the Guangzhou-based, state-owned 21st Century Business Herald that the French company had paid 503 doctors a total of $274,000 to prescribe Sanofi products, disguising the payments as grants for research programs.
Sanofi has announced that the Food and Drug Administration's Nonprescription Drugs Advisory Committee (NDAC) voted 10 to 6, with 2 abstentions, recommending approval of Nasacort ® AQ Nasal Spray (triamcinolone acetonide) for over-the-counter use in the U.S.
The Paris-based drugmaker reported Thursday that net profit shrank 62 percent to 444 million euros ($592 million) in the April to June quarter, as the loss of patent on once-popular blood-thinner Plavix compounded further massive financial charges related to the company's past mergers and acquisitions.
Sanofi Pasteur, the vaccines division of Sanofi, announced today that the first lots of Fluzone@ (Influenza Virus Vaccine) for the 2013-2014 season have been released by the U.S. Food and Drug Administration (FDA) for U.S. distribution and were shipped July 24
Sanofi announced today that the first Phase 3 study results (EDITION I) for its investigational new insulin U300 showed equivalent blood sugar control with fewer night-time low blood sugar events compared to Lantus® (insulin glargine [rDNA origin] injection).
The National Institute for Health and Care Excellence issued draft guidance recommending against NHS reimbursement of Sanofi's Zaltrap (aflibercept) for treating patients with metastatic colorectal cancer that is resistant to or has progressed after an oxaliplatin containing regimen. The drug was approved for this use in Europe in February.
A group of Jefferies & Co. analysts said yesterday that drug companies are putting more emphasis on restructuring and spinning off parts of their business, and that those moves will be a critical factor in stock performance in 2013 and 2014.
A new asthma drug being developed by Sanofi and Regeneron Pharmaceuticals may help patients whose condition is not well controlled by existing medicines, according to the results of a small clinical trial released Tuesday. In the 12-week study, the number of asthma attacks or other outbreaks of symptoms decreased by 87 percent in those getting the drug, Dupilumab, compared with those getting a placebo.
France's antitrust authority on Tuesday fined Sanofi 40.6 million euros ($52.6 million) for a "smear campaign" designed to limit sales of generic versions of Plavix. The ruling on the drug, which last year generated global sales of nearly 2.1 billion euros ($2.7 billion), follows a complaint by Teva.
Berlin's renowned Charite hospital said Monday it plans to investigate allegations that patients in communist East Germany were used as unwitting guinea pigs in medical trials for Western drug companies. Claims that the dictatorship allowed tests that would have been considered unethical or even illegal in the West were first made shortly after German reunification in 1990, but no wrongdoing was found at the time.
French drug maker Sanofi said Thursday its net profit was slashed in the first quarter from a year earlier as falling sales and patent losses on key drugs combined to hammer earnings. Sanofi's net profit was €1 billion ($1.3 billion) in the January-March quarter, down 45 percent from €1.8 billion...
- Page 1